CD1C and rheumatoid arthritis: We found a negative-feedback control of DC activation, mediated by miR-34a governing immunosuppressive AXL pathway activation, that is aberrant in circulating, SF and synovial tissue CD1c+ DCs of RA patients; and that also contributes to experimental arthritis.